AIM - AIM ImmunoTech commences phase 2 study of Ampligen for treatment of pancreatic cancer

• AIM ImmunoTech ( NYSE: AIM ) on Thursday said it had commenced its phase 2 study of cancer treatment Ampligen for pancreatic cancer after getting an approval for the trial protocol from an Institutional Review Board (IRB).
• "Receiving IRB approval for our Phase 2 study of Ampligen for the treatment of (locally advanced pancreatic cancer) is the pivotal precursor to the recruitment, enrollment and treatment of patients with locally advanced pancreatic cancer," AIM CEO Thomas Equels said in a statement .
• The mid-stage study is expected to enroll about 90 subjects in up to 30 centers across the U.S. and Europe, AIM said.
• AIM's contract research organization for the study expects sites to be open and recruiting patients in late Q3 or early Q4 of this year.
• AIM stock -0.9% to $0.74 in morning trading.

For further details see: